Immune disease dialogue of chemokine-based cell communications as revealed by single-cell RNA sequencing meta-analysis
Year: 2024
Type: article
Abstract: Immune-mediated diseases are characterized by aberrant immune responses, posing significant challenges to global health. In both inflammatory and autoimmune diseases, dysregulated immune reactions mediated by tissue-residing immune and non-immune cells precipitate chronic inflammation and tissue damage that is amplified by peripheral immune cell extravasation into the tissue. Chemokine receptors are pivotal in orchestrating immune cell migration, yet deciphering the signaling code across cell types, diseases and tissues remains an open challenge. To delineate disease-specific cell-cell communications involved in immune cell migration, we conducted a meta-analysis of publicly available single-cell RNA sequencing (scRNA-seq) data across diverse immune diseases and tissues. Our comprehensive analysis spanned multiple immune disorders affecting major organs: atopic dermatitis and psoriasis (skin), chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (lung), ulcerative colitis (colon), IgA nephropathy and lupus nephritis (kidney). By interrogating ligand-receptor (L-R) interactions, alterations in cell proportions, and differential gene expression, we unveiled intricate disease-specific and common immune cell chemoattraction and extravasation patterns. Our findings delineate disease-specific L-R networks and shed light on shared immune responses across tissues and diseases. Insights gleaned from this analysis hold promise for the development of targeted therapeutics aimed at modulating immune cell migration to mitigate inflammation and tissue damage. This nuanced understanding of immune cell dynamics at the single-cell resolution opens avenues for precision medicine in immune disease management.
Source: Frontiers in Systems Biology
Institution: Sanofi (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,125
Funders: Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Sanofi, Rheumatology Research Foundation, Lupus Research Alliance, National Institutes of Health, Takeda Pharmaceuticals International, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Janssen Research and Development
Awards: G1337560105, G1360281539, G1362265753, G169455022, G173065605, G188243792, G1972444143, G2198129094, G2485223290, G2636385648, Evolving Adaptive and Effector Mechanisms from Pre-RA Through Established Disease, G3640815516, G3657101678, G3668774724, G4698129410, G4813776453, G4829937125, G668334306, G703087348, G7316078541, G752708747, G882380370, G9000001696, G9000002510, G9000003399, G9000004833, G9000005140, G9000008302, G9000014358, G9000017462, G9000176611
OpenAlex ID: W4405347378